LETARSHA CAMPBELL: Open Payments
NPI 1205124310 · CLINTON, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,731 in 83 payments from 15 companies in 2025. Trend: 2023 $1,394 · 2024 $1,337 · 2025 $1,731
Food & beverage: $1,731
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 27 | $492 |
| Janssen Pharmaceuticals, Inc | 13 | $357 |
| Otsuka America Pharmaceutical, Inc. | 8 | $157 |
| ABBVIE INC. | 7 | $143 |
| Neurocrine BioSciences, Inc. | 5 | $112 |
| Axsome Therapeutics, Inc. | 3 | $81 |
| Supernus Pharmaceuticals, Inc. | 3 | $68 |
| Vanda Pharmaceuticals Inc. | 3 | $68 |
| Alkermes, Inc. | 3 | $64 |
| Lundbeck LLC | 2 | $39 |
Products named: CAPLYTA, INVEGA SUSTENNA, VRAYLAR, INGREZZA, ABILIFY ASIMTUFII, REXULTI, Auvelity, Qelbree.
Industry payments across LA — which companies pay providers there.
